Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 10/20 | 0.42 |
| ▸ | KDR | P35968 | 5/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.42 |
| ▸ | FLT4 | P35916 | 4/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 9/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4664124 | 0.99 | FLT1 (0.42) | FLT1KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL4665965 | 0.88 | FLT1 (0.42) | FLT1KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL4666065 | 0.88 | FGFR1 (0.42) | FLT1KDRFGFR1FGFR2FGFR4 | |
| Hydrochloric Acid SCHEMBL4667705 | 0.87 | FGFR1 (0.42) | FLT1KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL4665962 | 0.83 | SRC (0.53) | FLT1SRCEGFR | |
| Hydrochloric Acid SCHEMBL4771269 | 0.83 | SRC (0.52) | FLT1SRCEGFR | |
| SCHEMBL4666487 | 0.77 | KDR (0.53) | FLT1KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL4665960 | 0.74 | SRC (0.49) | FLT1KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL4664094 | 0.73 | KDR (0.52) | FLT1KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL4666088 | 0.71 | PRKCQ (0.52) | SRCPDGFRBEGFRPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | claimed |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | claimed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | claimed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | claimed |
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | HENNEQUIN LAURENT FRANCOIS ANDRE | 2008-12-18 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | VEGFA, FLT1, FLT4 | FLT1 2/4885KDR 4/4885FGFR1 99/4885 |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | VEGFA, FLT1, FLT4 | FLT1 2/4885KDR 5/4885FGFR1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.